Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Oncology

Survivorship and Beyond: Navigating Life After Treatment

At a Glance

After completing bone sarcoma treatment, patients require lifelong monitoring to check for cancer recurrence and manage the late effects of chemotherapy. A specialized survivorship care plan will guide your ongoing schedule for scans, heart monitoring, and kidney tests.

Finishing active treatment for bone sarcoma is a major milestone, but it is not the end of the journey. Because these cancers are aggressive and the treatments are intensive, the “survivorship” phase requires a dedicated, lifelong commitment to monitoring. This process focuses on two main goals: catching any signs of the cancer returning as early as possible and managing the “late effects” of the chemotherapy, radiation, and surgery you received.

The Surveillance Roadmap

Recurrence is most common in the first few years after treatment, so your “check-ups” will be very frequent at first [1]. While every hospital has a slightly different protocol, a typical schedule often follows this pattern:

  • Years 1–2: Every 3 months. You will likely have a physical exam, a chest CT to check the lungs, and an MRI or X-ray of the original tumor site [2][1].
  • Years 3–5: Every 6 months. Most recurrences “plateau” (level off) after about 4 to 5 years, allowing the time between scans to increase [3][1].
  • Year 5 and Beyond: Annually. While the risk of the original cancer returning drops significantly after 5 years, lifelong monitoring is still recommended for other health reasons [4][5].

Dealing with “Scanxiety”

It is completely normal to feel intense anxiety in the days and weeks leading up to your follow-up scans—a phenomenon often called “scanxiety.” Acknowledging this feeling and having a support system in place can help you manage the emotional weight of these appointments.

Understanding Late Effects of Treatment

The powerful drugs used to save your life can sometimes cause health issues years or even decades later. Knowing what to watch for allows for early intervention.

Heart Health (Doxorubicin)

Doxorubicin (the “A” in MAP or the “D” in VDC/IE) is known to potentially weaken the heart muscle, a condition called cardiotoxicity [6].

  • The Risk: It can lead to a lower “ejection fraction” (how well your heart pumps blood) [7].
  • Monitoring: You should have regular echocardiograms (heart ultrasounds) to monitor your heart function for the rest of your life [7][8].

Hearing and Kidneys (Cisplatin)

Cisplatin can be tough on the ears and the kidneys.

  • Ototoxicity: It can cause permanent, high-frequency hearing loss or tinnitus (ringing in the ears) [9][10]. If you have trouble hearing in crowded rooms, tell your doctor.
  • Nephrotoxicity: It can reduce kidney function over time [11]. Regular blood tests to check your “creatinine” levels are essential.

Secondary Malignancies

Survivors of bone sarcoma have a slightly higher risk of developing a second, different type of cancer later in life, such as leukemia or a radiation-induced sarcoma (if you received radiation therapy) [5][12]. This is why staying “in the system” with a survivorship team is so important—they are trained to spot these rare but serious issues early [12].

The Role of Survivorship Clinics

A specialized survivorship clinic is staffed by experts who understand the unique needs of sarcoma survivors [13]. They provide you with a Survivorship Care Plan (SCP)—a document that summarizes your exact diagnosis, the total doses of every drug you received, and a clear “to-do list” for your future health [14][15]. Research shows that patients who stay engaged with these specialized clinics often have better overall health outcomes [14]. Moving forward, your survivorship team becomes your partner in ensuring that you not only survive but thrive.

Common questions in this guide

How often do I need follow-up scans after bone sarcoma treatment?
In the first two years, you will typically have scans every three months. Between years three and five, scans occur every six months. After five years, you will usually transition to annual check-ups to monitor your overall health.
How does doxorubicin chemotherapy affect my heart later in life?
Doxorubicin can potentially weaken the heart muscle over time, leading to cardiotoxicity. To catch any issues early, you will need regular echocardiograms for the rest of your life to monitor how well your heart pumps blood.
What are the long-term side effects of cisplatin?
Cisplatin can cause permanent, high-frequency hearing loss or ringing in the ears, known as tinnitus. It can also reduce your kidney function over time, making regular hearing tests and blood work essential.
What is a Survivorship Care Plan?
A Survivorship Care Plan is a personalized document created by a specialized clinic. It summarizes your exact diagnosis, lists the total doses of chemotherapy you received, and provides a clear schedule for your future health monitoring.
Is it normal to feel anxious before my follow-up scans?
Scanxiety is the intense anxiety or worry patients feel in the days leading up to their follow-up scans. It is a completely normal emotional response, and joining a support group or seeking counseling can help you cope during these visits.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can I have a written Survivorship Care Plan that lists my cumulative doses of Doxorubicin and Cisplatin?
  2. 2.What is our specific schedule for chest CT scans and local MRIs over the next two years?
  3. 3.Should I be seeing a cardio-oncologist for regular heart check-ups given my Doxorubicin treatment?
  4. 4.How often should my hearing and kidney function be tested?
  5. 5.Are there specific symptoms of secondary cancers I should be looking for?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    The significance of surveillance imaging in children with Ewing sarcoma and osteosarcoma.

    Brekke SG, Lucke A, Hasle H, Baad-Hansen T

    Pediatric hematology and oncology 2024; (41(4)):273-282 doi:10.1080/08880018.2024.2311407.

    PMID: 38345039
  2. 2

    Imaging of pediatric bone tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.

    Cederberg KB, Iyer RS, Chaturvedi A, et al.

    Pediatric blood & cancer 2023; (70 Suppl 4()):e30000 doi:10.1002/pbc.30000.

    PMID: 36250990
  3. 3

    Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment.

    Goedhart LM, Ho VKY, Ploegmakers JJW, et al.

    Journal of bone oncology 2023; (38()):100466 doi:10.1016/j.jbo.2022.100466.

    PMID: 36578650
  4. 4

    Cumulative Burden of Chronic Health Conditions in Adult Survivors of Osteosarcoma and Ewing Sarcoma: A Report from the St. Jude Lifetime Cohort Study.

    Bishop MW, Ness KK, Li C, et al.

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2020; (29(8)):1627-1638 doi:10.1158/1055-9965.EPI-20-0076.

    PMID: 32499311
  5. 5

    Post-treatment late and long-term effects in bone sarcoma: A scoping review.

    Khan K, Kane K, Davison Z, Green D

    Journal of bone oncology 2025; (52()):100671 doi:10.1016/j.jbo.2025.100671.

    PMID: 40206491
  6. 6

    Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury.

    Avagimyan A, Pogosova N, Kakturskiy L, et al.

    Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2024; (73()):107683 doi:10.1016/j.carpath.2024.107683.

    PMID: 39111556
  7. 7

    Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.

    Henriksen PA

    Heart (British Cardiac Society) 2018; (104(12)):971-977 doi:10.1136/heartjnl-2017-312103.

    PMID: 29217634
  8. 8

    Doxorubicin targets multiple players: A new view of an old problem.

    Cappetta D, Rossi F, Piegari E, et al.

    Pharmacological research 2018; (127()):4-14 doi:10.1016/j.phrs.2017.03.016.

    PMID: 28336372
  9. 9

    Cisplatin is retained in the cochlea indefinitely following chemotherapy.

    Breglio AM, Rusheen AE, Shide ED, et al.

    Nature communications 2017; (8(1)):1654 doi:10.1038/s41467-017-01837-1.

    PMID: 29162831
  10. 10

    Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities.

    Trendowski MR, El Charif O, Dinh PC, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2019; (25(4)):1147-1155 doi:10.1158/1078-0432.CCR-18-2244.

    PMID: 30305294
  11. 11

    Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial.

    Ghonaim E, El-Haggar S, Gohar S

    Medical oncology (Northwood, London, England) 2021; (38(9)):108 doi:10.1007/s12032-021-01558-y.

    PMID: 34357466
  12. 12

    Osteosarcoma and second malignant neoplasms: a case series.

    Geary RL, Corrigan LR, Carney DN, Higgins MJ

    Irish journal of medical science 2019; (188(4)):1163-1167 doi:10.1007/s11845-019-02027-2.

    PMID: 31054046
  13. 13

    Survivorship therapy needs after radiotherapy for head and neck cancer: surveying opportunities for growth (STRONG).

    Larson A, Ma Y, Sun Z, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025; (33(5)):403 doi:10.1007/s00520-025-09429-2.

    PMID: 40299080
  14. 14

    Survivorship care and mortality in a contemporary and diverse cohort of childhood cancer survivors.

    Ji X, Williamson Lewis RS, Wasilewski-Masker K, et al.

    Journal of the National Cancer Institute 2025; doi:10.1093/jnci/djaf276.

    PMID: 41002187
  15. 15

    Care Models and Barriers to Long-Term Follow-Up Care Among Childhood Cancer Survivors and Health Care Providers in Asia: A Literature Review.

    Cai J, Cheung YT, Hudson MM

    JCO global oncology 2024; (10()):e2300331 doi:10.1200/GO.23.00331.

    PMID: 38452303

This page provides educational information about bone sarcoma survivorship and late treatment effects. Always consult your oncology team or survivorship clinic for personalized medical advice regarding your ongoing follow-up care.

Get notified when new evidence is published on Bone sarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.